Type 2 Diabetes Mellitus Completed Phase Trials for Exenatide (DB01276)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00775684Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell MassTreatment
NCT01136798Impact of Exenatide on Sleep in Type 2 DiabetesTreatment
NCT01364584Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 DiabetesOther
NCT01046721Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its MechanismsBasic Science
NCT01677104The Microvascular Function of GLP-1 and Its AnaloguesDiagnostic
NCT01089569Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin GlargineTreatment
NCT02150707The Differential Effects of Diabetes Therapy on Inflammation
NCT00635492CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
NCT00855439Evaluation of Exenatide in Patients With Diabetic NeuropathyTreatment
NCT01060059Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
NCT01473147Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic PatientsTreatment
NCT02456428Incretin-based Drugs and the Risk of Heart Failure
NCT02895672GLP-1/Basal Insulin Combination Therapy
NCT02090673Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
NCT01147627Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsTreatment
NCT02475499Incretin-based Drugs and Pancreatic Cancer
NCT02476760Incretin-based Drugs and Acute Pancreatitis
NCT01281228The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes